Evidence map›Paper›PMID 35537720›Full record

Trial reportSaudi medical journal2022

Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention.

Seyed Mohammad H Adel, Fateme Jorfi, Hoda Mombeini, Homeira Rashidi, Saad Fazeli

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Saudi medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 11 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 11 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Pooled it
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Seyed Mohammad H AdelFrom the Department of Cardiology (Adel, Jorfi, Mombeini, Fazeli), from the Atherosclerosis Research Center (Adel, Jorfi, Mombeini), and from the Department of Internal Medicine (Rashidi), Ahvaz Jundishapur University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran.
Fateme JorfiFrom the Department of Cardiology (Adel, Jorfi, Mombeini, Fazeli), from the Atherosclerosis Research Center (Adel, Jorfi, Mombeini), and from the Department of Internal Medicine (Rashidi), Ahvaz Jundishapur University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran.
Hoda MombeiniFrom the Department of Cardiology (Adel, Jorfi, Mombeini, Fazeli), from the Atherosclerosis Research Center (Adel, Jorfi, Mombeini), and from the Department of Internal Medicine (Rashidi), Ahvaz Jundishapur University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran.
Homeira RashidiFrom the Department of Cardiology (Adel, Jorfi, Mombeini, Fazeli), from the Atherosclerosis Research Center (Adel, Jorfi, Mombeini), and from the Department of Internal Medicine (Rashidi), Ahvaz Jundishapur University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran.
Saad FazeliFrom the Department of Cardiology (Adel, Jorfi, Mombeini, Fazeli), from the Atherosclerosis Research Center (Adel, Jorfi, Mombeini), and from the Department of Internal Medicine (Rashidi), Ahvaz Jundishapur University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran.
Ahvaz Jundishapur University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo study the effects of low dose of empagliflozin on improving outcomes in diabetic patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI).

methodsThis double-blind controlled clinical trial was carried out on 93 diabetic patients (56 males and 37 females, mean age of 56.55 years) with ACS who underwent PCI at 2 university teaching hospitals in 2020, Ahvaz, Iran. The patients were randomly assigned to receive empagliflozin (10 mg once daily) or placebo at similar doses for 6 months after PCI. In addition, to standard treatments with another hypoglycemic agent. Cardiovascular outcomes (including all-cause mortality, coronary revascularization, rehospitalization due to unstable angina, hospitalization due to heart failure, cardiovascular death, non-fetal myocardial infarction, and non-fetal stroke) were evaluated during period of 6 months follow-up after the empagliflozin treatment.

resultsThere was no significant difference between the low dose empagliflozin and placebo groups after treatment in terms of cardiovascular mortality (2.2% versus [vs.] 4.2%;

conclusionThe results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.

Indexed as

Acute Coronary SyndromeDiabetes Mellitus, Type 2Percutaneous Coronary InterventionAngina, UnstableBenzhydryl CompoundsFemaleGlucosidesHumansMaleMiddle AgedTreatment OutcomeBenzhydryl CompoundsempagliflozinGlucosidesacute coronary syndromediabetesempagliflozin

Identifiers

PMID35537720
PMCPMC9280595
OpenAlexW4280514510

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.